Catalog No.S3021 Synonyms: SR141716

Rimonabant Chemical Structure

Molecular Weight(MW): 463.79

Rimonabant is a selective antagonist of CB1 with IC50 of 13.6 nM and EC50 of 17.3 nM in hCB1 transfected HEK 293 membrane.

Size Price Stock Quantity  
In DMSO USD 120 In stock
USD 90 In stock
USD 170 In stock
USD 270 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective Cannabinoid Receptor Inhibitors

Biological Activity

Description Rimonabant is a selective antagonist of CB1 with IC50 of 13.6 nM and EC50 of 17.3 nM in hCB1 transfected HEK 293 membrane.
Features Efficacious to induce weight reduction and improvements in cardiometabolic risk factors, however was withdrawn in 2009 due to severe depressive disorder and anxiety.
hCB1 [1]
(Cell-free assay)
hCB2 [1]
(Cell-free assay)
13.6 nM 1.64 μM
In vitro

Rimonabant dose-dependently reduces ACAT activity in Raw264.7macrophages with IC50 of 2.9 μM and isolated peritoneal macrophages. Rimonabant inhibits ACATactivity in intact CHO-ACAT1 and CHO-ACAT2 cells and in cell-free assays with approximately equal efficiency with IC50 of 1.5 μM and 2.2 μM for CHO-ACAT1 and CHO-ACAT2, respectively. Consistent with ACAT inhibition, Rimonabant treatment blocks ACAT dependent processes in macrophages, oxysterol-induced apoptosis and acetylated-LDL induced foam cell formation. [2] Rimonabant antagonizes the inhibitory effects of cannabinoid receptor agonists on both mouse vas deferens contractions and adenylyl cyclase activity in rat brain membranes in a concentration-dependent manner. [3] Rimonabant significantly reduces cell growth and induces cell death of human colorectal cancer cells (DLD-1, CaCo-2 and SW620). Rimonabant is able to alter cell cycle distribution in all the cell lines tested. Particularly, Rimonabant produces a G2/M cell cycle arrest in DLD-1 cells without inducing apoptosis or necrosis. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CHO cells NYO0T29CTnWwY4Tpc44h[XO|YYm= NVnFUWcySWKrbHn0fUB1dyCmaYPwcIFk\SCdM1jdMXNTNSBzNEG3NVZCKGKrbnTpcochfG9iaIXtZY4hS0JzIILlZ4VxfG:{IHX4dJJme3OnZDDpckBEUE9iY3XscEBu\W2kcnHu[ZMtKEurPUiuPUBvVQ>? MWSxNFQ3PTV3Mh?=
CHO cells M2HzPWZ2dmO2aX;uJIF{e2G7 NUPEcXJHSW62YXfvcol{fGmlIHHjeIl3cXS7IITve4Fz\HNiY3HucoFjcW6xaXSgdoVk\XC2b4KgNUBmgHC{ZYPz[YQh[XNiW{PIYWFz[WOqaXTvcolkKGGlaXSgdoVt\WG|ZTDpckBEUE9iY3XscJMtKEumPUKuOVEhdk1? NWe5U4lwOTR5M{[yOFM>
HEK293 cells M160NmZ2dmO2aX;uJIF{e2G7 MXXJcY1m\GmjdHWgZY51[WexbnnzeE9Kdn[ncoPlJIFod26rc4SgZYN1cX[rdImgZZQhcGWvYXfncJV1cW6rbj30ZYdo\WRiaIXtZY4hS0JzIILlZ4VxfG:{IHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNiYYPz[ZN{\WRiYYOgdoV3\XK|YXygc4YhOSC3TTDDVFU2NDl2MD3pcoR2[2WmIHnubIljcXSrb36gc4YhPSC3TTDmc5J{c2:uaX6tbY5lfWOnZDDjRW1RKGGlY4XteYxifGmxbjDifUBscW6ndHnjJINCVVBiYYPzZZk> NWntVXBkOjZ{MEO2OVg>
CHOK1 cells M2P4T2Z2dmO2aX;uJIF{e2G7 MXnBcpRi\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJGNDOSC{ZXPldJRweiCneIDy[ZN{\WRiaX6gR2hQUzFiY3XscJMh[nlibIXjbYZmemG|ZTDhd5NigSxiSVO1NF0xNjF{IN88US=> M36y[VE5OjR|N{Gx
HEK293 cells M2nTXmZ2dmO2aX;uJIF{e2G7 NI[zVJlFcXOybHHj[Y1mdnRib3[gX|NJZUOSLUW1PVQxKG[{b32gbJVu[W5icnXjc41jcW6jboSgR2IzWiCneIDy[ZN{\WRiaX6gTGVMOjl|IHPlcIx{NCCLQ{WwQVEvPjNzMTFOwG0> MojuNVk2OzB4OUe=
SF9 cells M1fmV2Z2dmO2aX;uJIF{e2G7 NGjuNppKdn[ncoPlJIFod26rc4SgZZQhcHWvYX6gR2IyKHKnY3XweI9zKGW6cILld5Nm\CCrbjDTSlkh[2WubIOgZZN{\XO|ZXSgZZMh\GWlcnXhd4UhcW5iR2TQ[4FudWGVIHzleoVtNCCLQ{WwQVEvOzVibl2= MVqxPFQ1QDN2MB?=
SF9 cells MV\GeY5kfGmxbjDhd5NigQ>? MYjBcpRi\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJGNDOiC{ZXPldJRweiCrbjDTSlkh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDDVE02PTl2MD3zeIlufWyjdHXkJGdVWGejbX3hV{BjcW6maX7nMEBMcT1yLkixOUDPxE1? NX\PNJl[OTh2NEizOFA>
HEK cells NWexUYpnTnWwY4Tpc44h[XO|YYm= NYDVdZdkTGm|cHzhZ4Vu\W62IH;mJHs{UF2FUD21OVk1OCCocn;tJIh2dWGwIILlZ49u[mmwYX70JGNDOiC{ZXPldJRweiCneIDy[ZN{\WRiaX6gTGVMKGOnbHzzMEBMcT1yLke5JO69VQ>? MU[xPFU4QTN6Nh?=
CHOK1 cells NF:wRpNHfW6ldHnvckBie3OjeR?= NHfPOnlCdnSjZ3;ubZN1KGGldHn2bZR6KGG2IHj1cYFvKEOEMTDy[YNmeHSxcjDlfJBz\XO|ZXSgbY4hS0iRS{GgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCFUD21OVk1OC2rbnT1Z4VlKHKnc4DvcpNmKGGodHXyJFExKG2rboOgZpkhT1SSZ3HtcYFcOzWVXTDibY5lcW6pIHHzd4F6NCCNaU2wMlAxOTZizszN MVSxPVM2OTFzMx?=
N1E-115 cells M1fo[2Z2dmO2aX;uJIF{e2G7 NXfQR4dEUW64ZYLz[UBi\2:waYP0JIFkfGm4aYT5JIF1KEOEMTDy[YNmeHSxcjDpckBud3W|ZTDONWUuOTF3IHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhX0mQIEW1MFIyOi1{LXnu[JVk\WRiRWLLNU8zKHCqb4PwbI9zgWyjdHnvckBifCBzIIXNJJRz\WG2ZXSgOUBucW6|IIDybY9zKHSxIGfJUkA2PSx{MUKtNkBkcGGubHXu[4Uh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz MnvRNlM{PTd|MEe=
RD-HGA16 cells NFTrO2ZHfW6ldHnvckBie3OjeR?= M1jNVGFvfGGpb37pd5Qh[WO2aY\peJkh[XRiQ1KxJJJm[2WydH;yJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW|c3XkJIlvKFKGLVjHRVE3KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gR3A2PTl2MD3pcoR2[2WmIHPhcINqfW1ibX;ibYxqgmG2aX;uJIJ6KG[udX;yc41mfHKrYzDpcYFocW6pIIDsZZRmKHKnYXTldkBidmGueYPpdy=> M{noVlI1QTR2N{O0

... Click to View More Cell Line Experimental Data

Methods Test Index PMID
Western blot
CD44 / Lgr5 / CD133 / EpCAM ; 

PubMed: 29354056     

Representative Western blot analysis of CD44, Lgr5, CD133 and EpCAM in total protein lysates from HCT116 cells. GAPDH was used as loading control.


PubMed: 29354056     

Representative Western blot analysis (left) of β-Catenin in total protein lysates from GTG7 cells. Right, densitometric analysis of β-Catenin normalized vs. GAPDH, used as loading control. Results are expressed as means ± SD of 3 independent experiments performed at least in duplicate (∗∗p < 0.01).

p-LRP6 / LRP6 / Lgr5 ; 

PubMed: 29354056     

Representative Western blot analysis of Lgr5, LRP6 and phosphorylated (Ser1490) LRP6. GAPDH was used as loading control.


PubMed: 29354056     

Confocal microscopy analysis of β-Catenin (red) in GTG7 cells treated with Rimonabant at indicated doses for 18 h. Nuclei were stained with Hoechst (blue fluorescence); GFP (green); Scale bar = 5 μm.

Lgr5 ; 

PubMed: 29354056     

Confocal microscopy analysis of Lgr5 (red fluorescence) in GTG7 cells treated with Rimonabant at indicated doses for 18 h. Nuclei were stained with Hoechst (blue fluorescence); GFP (green); Scale bar = 5 μm.

In vivo Rimonabant is administered intraperitoneally or orally potently and dose-dependently antagonize classical pharmacological and behavioural effectos of cannabinoid receptor agonists. [3] In the mouse model of azoxymethane-induced colon carcinogenesis, Rimonabant significantly decreased aberrant crypt foci (ACF) formation, which precedes colorectal cancer. [4] Rimonabant (10 mg/kg by gavage) is fed for 2 weeks to 3-month-old male obese Zucker rats as an impaired glucose tolerance model and for 10 weeks to 6-month-old male obese Zucker rats as a model of the metabolic syndrome. RANTES (Regulated upon Activation, Normal T cell Expressed, and Secreted) and MCP-1 (monocyte chemotactic protein-1) serum levels are increased in obese vs lean Zucker rats and significantly reduced by long-term treatment with Rimonabant, which slowes weight gain in rats with the metabolic syndrome. Neutrophils and monocytes are significantly increased in young and old obese vs lean Zucker rats and lowered by Rimonabant. Platelet-bound fibrinogen is significantly enhanced in obese vs lean Zucker rats of both age, and is reduced by Rimonabant. Platelets from obese rats are more sensitive to thrombin-induced aggregation and adhesion to fibrinogen, which are both attenuated by Rimonabant therapy. [5]


Kinase Assay:[1]
- Collapse

Radioligand Binding Assay:

Human CB1 and CB2 stably transfect HEK 293 cells and cell membrane is purified. 0.2-8 μg of the purified membrane is incubated with 0.75 nM [3H] CP55,940 and Rimonabant in the incubation buffer (50 mM Tris-HCl, 5 mM MgCl2, 1 mM EDTA, 0.3%BSA, pH 7.4). The non-specific binding is defined in the presence of 1 μM of CP55,940. The reactions are incubated for one and a half hours at 30 °C in Multiscreen. The reactions are terminated by manifold filtration and washed four times with ice-cold wash buffer (50mM Tris, pH 7.4, 0.25% BSA).The radioactivity bound to the filters is measured by Topcount. The IC50 is determined as the concentration of Rimonabant required to inhibit 50% of the binding of [3H] CP55,940 and calculated by non-linear regression.
Cell Research:[2]
- Collapse
  • Cell lines: Raw 264.7 cells
  • Concentrations: 0,1,4 μM
  • Incubation Time: 17 hours
  • Method: Raw 264.7 cells (2 × 106 /well) in 12-well plates are rinsed with PBS and refed culture media supplemented with varying amounts of Rimonabant 1 hour prior to supplementation with 7-ketocholesterol (7KC). All wells are adjusted to receive equal amounts of vehicle. Following 16-hour incubation, caspase-3 and caspase 3-like activity are determined using a fluorogenic substrate (Ac-DEVD-AFC) and a spectrofluorometer equipped with a microplate reader.
    (Only for Reference)
Animal Research:[3]
- Collapse
  • Animal Models: Male mice and male rats
  • Formulation: Rimonabant is dissolved in two drops of Tween 80, diluted in distilled water.
  • Dosages: 20 ml/kg (mice) and 5 ml/kg (rats)
  • Administration: Rimonabant is administered i.p. (30 minutes) or p.o. (1hour) before the i.v. injection of WIN55212-2.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 25 mg/mL (53.9 mM)
Ethanol 2 mg/mL (4.31 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 463.79


CAS No. 168273-06-1
Storage powder
in solvent
Synonyms SR141716

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00750347 Completed Drug: Rimonabant and Paracetamol and placebo Pain University Hospital Clermont-Ferrand September 2008 Phase 1
NCT00656487 Completed Drug: rimonabant|Drug: placebo Cannabis Dependence|Cannabis Withdrawal The Scripps Research Institute|National Institute on Drug Abuse (NIDA) April 30 2008 Phase 2
NCT00546325 Completed Drug: Rimonabant|Drug: Placebo Diabetes Mellitus Type 2 Sanofi October 2007 Phase 3
NCT00525681 Completed Drug: cyclosporine A|Drug: tacrolimus Renal Transplantation University of Oslo School of Pharmacy September 2007 Phase 4
NCT00584389 Terminated Drug: rimonabant|Behavioral: Dietary intervention Obesity University of Surrey|European Foundation for the Study of Diabetes|Royal Surrey County Hospital NHS Foundation Trust July 2007 Phase 4
NCT01041170 Completed Drug: THC|Drug: Rimonobant|Drug: Rimonabant Cannabis|Dependence National Institute on Drug Abuse (NIDA)|National Institutes of Health Clinical Center (CC) April 16 2006 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Cannabinoid Receptor Signaling Pathway Map

Related Cannabinoid Receptor Products

Tags: buy Rimonabant | Rimonabant ic50 | Rimonabant price | Rimonabant cost | Rimonabant solubility dmso | Rimonabant purchase | Rimonabant manufacturer | Rimonabant research buy | Rimonabant order | Rimonabant mouse | Rimonabant chemical structure | Rimonabant mw | Rimonabant molecular weight | Rimonabant datasheet | Rimonabant supplier | Rimonabant in vitro | Rimonabant cell line | Rimonabant concentration | Rimonabant nmr
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID